Abstract
The acute administration of atorvastatin has been reported to reduce myocardial infarct size in animal studies. However, this cardioprotective effect is lost with the chronic administration of atorvastatin, although it can be recaptured by administering an acute high-dose of atorvastatin. We hypothesised that pre-treatment with high-dose atorvastatin, on a background of chronic standard ‘statin’ therapy, would reduce myocardial injury in patients undergoing elective coronary artery bypass graft (CABG) surgery. One hundred and one consenting patients undergoing elective CABG surgery at a single tertiary cardiac centre were recruited into two randomised controlled, single-blinded clinical studies. Study 1: 45 patients were randomised to receive either 160 mg of atorvastatin 2 h preoperatively and 24 h following surgery or their standard statin therapy. Study 2: 56 patients were randomised to receive either 160 mg of atorvastatin 12 h preoperatively and 24 h following surgery or their standard statin therapy. Blood samples for troponin T and creatine kinase were taken prior to surgery and then at 6, 12, 24, 48 and 72 h post-surgery. Cardiac enzyme levels at each time point and the total area-under curve (AUC) were calculated. The group characteristics and surgical methods were well matched. High-dose atorvastatin was not associated with any significant side effects. There was no significant difference in serum troponin T or creatine kinase in either study at each time point or over 72 h. Study 1: AUC, troponin T: atorvastatin 29.6 ± 34.8 μg/L versus control 25.0 ± 22.0 μg/L:P > 0.05. Creatine kinase: atorvastatin 33,544 ± 20,063 IU/L versus control 30,620 ± 10,776 IU/L:P > 0.05. Study 2: AUC, troponin T: atorvastatin 21.8 ± 14.3 μg/L versus control 20.9 ± 8.7 μg/L:P > 0.05. Creatine kinase: atorvastatin 36,262 ± 28,821 IU/L versus control 33,448 ± 14,984:P > 0.05. There were no differences in postoperative outcomes. We report that the administration of high-dose atorvastatin to low risk patients undergoing elective CABG surgery, who are already on standard dose ‘statin’ therapy is safe, but does not further reduce perioperative myocardial injury.
Similar content being viewed by others
References
Bell RM, Yellon DM (2003) Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41:508–515. doi:10.1016/S0735-1097(02)02816-4
Birnbaum Y, Lin Y, Ye Y, Martinez JD, Huang MH, Perez-Polo JR, Uretsky BF (2007) Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. J Am Coll Cardiol 49:184A. doi:10.1016/j.jacc.2007.01.039
Birnbaum Y, Ye Y, Lin Y, Freeberg SY, Nishi SP, Martinez JD, Huang MH, Uretsky BF, Perez-Polo JR (2006) Augmentation of myocardial production of 15-epi-lipoxin-A(4) by pioglitazone and atorvastatin in the rat. Circulation 114:929–935. doi:10.1161/circulationAHA.106.629907
Collard CD, Body SC, Shirnan SK, Wang S, Mangano DT (2006) Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 132:392–400. doi:10.1016/j.jtcvs.2006.04.009
Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A (2009) Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for reduction of myocardial damage during angioplasty) randomized trial. J Am Coll Cardiol 54:558–565. doi:10.1016/j.jacc.2009.05.028
Domanski MJ, Mahaffey K, Hasselblad V, Brener SJ, Smith PK, Hillis G, Engoren M, Alexander JH, Levy JH, Chaitman BR, Broderick S, Mack MJ, Pieper KS, Farkouh ME (2011) Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA 305:585–591. doi:10.1001/jama.2011.99
Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95:8880–8885
Engelhorn T, Doerfler A, Heusch G, Schulz R (2006) Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats. Neurosci Lett 406:92–96. doi:10.1016/j.neulet.2006.07.022
Ferdinandy P, Schulz R, Baxter GF (2007) Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59:418–458. doi:10.1124/pr.107.06002
Hausenloy DJ, Mwamure P, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM (2007) Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet 370:575–579. doi:10.1016/S0140-6736(07)61296-3
Hausenloy DJ, Baxter G, Bell R, Botker HE, Davidson SM, Downey J, Heusch G, Kitakaze M, Lecour S, Mentzer R, Mocanu MM, Ovize M, Schulz R, Shannon R, Walker M, Walkinshaw G, Yellon DM (2010) Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol 105:677–686. doi:10.1007/s00395-010-0121-4
Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischaemia–reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 61:448–460. doi:10.1016/j.cardiores.2003.09.024
Hausenloy DJ, Yellon DM (2007) Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 12:217–234. doi:10.1007/s10741-007-9026-1
Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C, Haude M, Heusch G, Erbel R (2002) Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 106:2180–2183. doi:10.1161/01.CIR.0000037520.89770.5E
Heusch G, Kleinbongard P, Bose D, Levkau B, Haude M, Schulz R, Erbel R (2009) Coronary microembolization: from bedside to bench and back to bedside. Circulation 120:1822–1836. doi:10.1161/CIRCULATIONAHA.109.888784
Iliodromitis EK, Andreadou I, Prokovas E, Zoga A, Farmakis D, Fotopoulou T, Ioannidis K, Paraskevaidis IA, Kremastinos DT (2010) Simvastatin in contrast to postconditioning reduces infarct size in hyperlipidemic rabbits: possible role of oxidative/nitrosative stress attenuation. Basic Res Cardiol 105:193–203. doi:10.1007/s00395-009-0078-3
Kulik A, Brookhart MA, Levin R, Ruel M, Solomon DH, Choudhry NK (2008) Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation 118:1785–1792. doi:10.1161/CIRCULATIONAHA.108.799445
Lehrke S, Steen H, Sievers HH, Peters H, Opitz A, Muller-Bardorff M, Wiegand UK, Katus HA, Giannitsis E (2004) Cardiac troponin T for prediction of short- and long-term morbidity and mortality after elective open heart surgery. Clin Chem 50:1560–1567. doi:10.1373/clinchem.2004.031468
Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, Dorge H, Stamm C, Wassmer G, Wahlers T (2008) Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J 29:1548–1549. doi:10.1093/eurheartj/ehn198
Ludman AJ, Yellon DM, Hausenloy DJ (2010) Cardiac preconditioning for ischaemia: lost in translation. Dis Model Mech 3:35–38. doi:10.1242/dmm.003855
Ludman A, Venugopal V, Yellon DM, Hausenloy DJ (2009) Statins and cardioprotection—more than just lipid lowering? Pharmacol Ther 122:30–43. doi:10.1016/j.pharmthera.2009.01.002
Mannacio VA, Iorio D, De AV, Di Lello F, Musumeci F (2008) Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg 136:1541–1548. doi:10.1016/j.jtcvs.2008.06.038
Mensah K, Mocanu MM, Yellon DM (2005) Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 45:1287–1291. doi:10.1016/j.jacc.2005.01.021
Pasceri V, Patti G, Nusca A, Pristopino C, Richichi G, Di Sciascio G (2004) Randomised trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (atorvastatin for reduction of myocardial damage during angioplasty) study. Circulation 110:674–678. doi:10.1161/01.CIR.0000137828.06205.87
Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G (2007) Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Results of the ARMYDA–ACS randomised trial. J Am Coll Cardiol 49:1272–1278. doi:10.1016/j.jacc.2007.02.025
Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, Kotze MJ, Heinonen TM, Black DM (2000) Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis 150:421–428. doi:10.1016/S0021-9150(99)00435-9
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285:1711–1718. doi:10.1001/jama.285.13.1711
Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, Schulz R, Heusch G (2009) Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 104:15–18. doi:10.1161/CIRCRESAHA.108.186429
Sun YM, Tian Y, Li X, Liu YY, Wang LF, Li J, Li ZQ, Pan W (2009) Effect of atorvastatin on expression of IL-10 and TNF-alpha mRNA in myocardial ischemia–reperfusion injury in rats. Biochem Biophys Res Commun 382:336–340. doi:10.1016/j.bbrc.2009.03.019
Szarszoi O, Maly J, Ostadal P, Netuka I, Besik J, Kolar F, Ostadal B (2008) Effect of acute and chronic simvastatin treatment on post-ischemic contractile dysfunction in isolated rat heart. Physiol Res 57:793–796
Takemoto M, Liao JK (2001) Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712–1719. doi:10.1161/hq1101.098486
(2008) The Society of Cardiothoracic Surgeons of Great Britain and Ireland. The 6th National Adult Cardiac Surgical Database Report. Dendrite Clinical Systems Ltd
Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhaeuser M, Peters J, Jakob H, Heusch G (2010) Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol 105:657–664. doi:10.1007/s00395-010-0104-5
Thygesen K, Alpert JS, White HD (2007) Universal definition of myocardial infarction. Circulation 116:2634–2653. doi:10.1161/CIRCULATIONAHA.107.187397
Venugopal V, Hausenloy DJ, Ludman A, Di Salvo C, Kolvekar S, Yap J, Lawrence D, Bognolo G, Yellon DM (2009) Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold blood cardioplegia: a randomised controlled trial. Heart 95:1567–1571. doi:10.1136/hrt.2008.155770
Venugopal V, Ludman A, Yellon DM, Hausenloy DJ (2009) Conditioning’ the heart during surgery. Eur J Cardiothorac Surg 35:977–987. doi:10.1016/j.ejcts.2009.02.014
Yao L, Chen GP, Lu X, Zheng LR, Mou Y, Hu SJ (2009) Effects of atorvastatin on calcium-regulating proteins: a possible mechanism to repair cardiac dysfunction in spontaneously hypertensive rats. Basic Res Cardiol 104:258–268. doi:10.1007/s00395-008-0751-y
Acknowledgments
We thank the British Heart Foundation for their continued support (Program Grant RG/03/007), and would like to thank the patients and staff at the Heart Hospital for their assistance throughout this study. This work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health‘s NIHR Biomedical Research Centres funding scheme.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ludman, A.J., Hausenloy, D.J., Babu, G. et al. Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial. Basic Res Cardiol 106, 1387–1395 (2011). https://doi.org/10.1007/s00395-011-0209-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00395-011-0209-5